Warning Letter Pilot Could Muddy Compliance Waters, Attorney Maintains
This article was originally published in The Gray Sheet
FDA's proposed warning letter pilot program could have the unintended effect of making it harder for industry to interpret certain compliance-related "gray areas," Thomas Muldoon, a partner in the Chicago law firm of Burditt & Radzius, asserted Oct. 27 at the Regulatory Affairs Professionals Society annual meeting in Washington, D.C.
You may also be interested in...
FDA's Center for Biologics Evaluation and Research should adopt the Center for Device and Radiological Health's warning letter pilot program for non-blood related devices, Gen-Probe Senior Director of Regulatory Affairs Glen Freiberg told an Oct. 6 session of the Regulatory Affairs Professionals Society annual meeting in Washington, D.C.
3D-printing company Carbon and in vitro diagnostics maker Resolution Medical announced plans to manufacture more than one million 3D-printed nasal swabs per week to test for COVID-19. See what Resolution Medical’s president Shawn Patterson said about it here.